louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00309816: Study of Sildenafil in Patient With Heart Failure.
Official title: Measurement of the Effect of Sildenafil Citrate (Viagra) on the Hemodynamics of Exercise Tolerance in Advanced Congestive Heart Failure.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Congestive Heart Failure
Keywords: Exercise stress test
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2006-04-03
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if sildenafil (Viagra) improves exercise tolerance.

Detailed description: Patients will undergo an exercise stress test. One dose of Sildenafil will then be given, followed by a one hour rest period. A repeat exercise stress test will then be repeated.

Eligibility criteria: Inclusion Criteria:

Age 18 - 75 Ejection fraction \<35% Heart failure limited by fatigue and shortness of breath -

Exclusion Criteria:

Inability to exercise. Patients with shortness of breath while resting. Patient requiring intravenous medication. Patients taking the following medications: nitroglycerine pill/patch/paste, isordil and Imdur

-

Primary outcomes:
measure: Patients will have exercise capacity measured by an exercise stress test before and after one dose of sildenafil.
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Marc J Semigran, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02181816: Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"
Official title: Azilsartan/Amlodipine (Zacras) Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Keywords: Pharmacological therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2014-07-04
Enrollment: 1090
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Hypertension

Brief summary: The purpose of this survey is to evaluate the safety and efficacy of long-term use of azilsartan/amlodipine combination tablets Low Dose (LD) \& High Dose (HD) (Zacras Combination Tablets LD \& HD) in hypertensive patients in daily medical practice.

Detailed description: This survey was designed to evaluate the safety and efficacy of long-term use of azilsartan/amlodipine combination tablets LD \& HD (Zacras Combination Tablets LD \& HD) in hypertensive patients in daily medical practice.

For adults, one azilsartan/amlodipine combination tablet (20 mg/2.5 mg \[for LD tablets\] or 20 mg/5 mg \[for HD tablets\] of azilsartan/amlodipine) is administered orally once daily. Azilsartan/amlodipine combination tablets should not be used as the first-line drug for the treatment of hypertension.

Eligibility criteria: Inclusion Criteria:

-Hypertensive patients

Exclusion Criteria:

-Hypertensive patients who meet any of the following conditions, \[1\] to \[3\], are excluded from the survey:

1. Patients with a history of hypersensitivity to any of the ingredients of azilsartan/amlodipine combination tablets or other dihydropyridine drugs
2. Patients who are pregnant or having possibilities of being pregnant
3. Diabetic patients taking aliskiren fumarate (excluding those with markedly poor blood pressure control even after other antihypertensive treatment)

Primary outcomes:
measure: Percentage of Participants Who Had One or More Adverse Events
timeFrame: Up to Month 12
Secondary outcomes:
measure: Systolic Office Blood Pressure
timeFrame: Baseline, Month 1, and final assessment point (up to Month 12)
measure: Diastolic Office Blood Pressure
timeFrame: Baseline, Month 1, and final assessment point (up to Month 12)
Other outcomes:
Locations:
city: Osaka
country: Japan
city: Tokyo
country: Japan
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01417416: Changes in the Permeability of the Blood Brain Barrier and Intestinal Barrier in Humans During Conditions of Stress and Immune Activation: in Vivo Studies
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Combat Training Stress
Lead sponsor: National University Hospital, Singapore
Sponsor class: OTHER
First posted: 2011-08-16
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy male troops during combat training

Brief summary: The relevance of BBB and IB permeability changes as a major precipitating cause for cognitive and digestive dysfunction in the military stress setting.


Eligibility criteria: Inclusion Criteria:

* Healthy male troops (aged 18-50 yrs) scheduled to be engaged in a protracted multi-day stressful field exercises.

Exclusion Criteria:

* Significantly systemic disease, including cardiovascular, psychiatric, neurological (including polyneuropathies) and endocrine disease including diabetes mellitus.
* No written informed consent obtained from subject.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00199316: Postoperative Pain Control After Kidney Surgery : a Comparison of Intrathecal Morphine Plus PCA and PCA Only
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Pain
Keywords: patient who recieve kidney surgery and Patient controlled anesthesia with spinal morphine, intrathecal
Lead sponsor: Khon Kaen University
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 80
Sex: ALL
Minimum age (years): 15
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: postoperative pain after kidney surgery is very high. We always use PCA for postopertive pain. But almost patients still had severe pain. We try to use spinal morphine before operation aims to reduce pain.


Eligibility criteria: Inclusion Criteria:

* kidney surgery who less than 60 years old.
* no underlying disease
* ASA less than 3

Exclusion Criteria:

* refuse spinal morphine
* history of morphine allery

Primary outcomes:
measure: pain score
timeFrame: 48 hours
Secondary outcomes:
measure: morphine consumption in PCA
timeFrame: 48 hours
measure: side effect
timeFrame: 48 hours
Other outcomes:
Locations:
city: Muang
country: Thailand
facility: Khon Kaen university, Srinagarind Hospital
state: Khon Kaen
Study officials:
affiliation: lecturer in Khon Kaen University
name: Polpun Boonmak, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03526016: Sleep Apnea in Acromegaly After Surgery
Official title: Effect of Transsphenoidal Surgery on Sleep Apnea in Patients With Acromegaly
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sleep Apnea
Keywords: Sleep Apnea
Acromegaly
Transsphenoidal surgery
Respiratory polygraphy
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2018-05-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Tertiary referral hospital

Brief summary: Sleep apnea is common in acromegaly and both diseases are independently associated with hypertension and insulin resistance contributing to increased morbidity and mortality. Respiratory polygraphy is a simpler alternative to in-laboratory polysomnography for the management of more symptomatic patients with obstructive sleep apnea.

The aim of this study is to evaluate the prevalence of sleep apnea by respiratory polygraphy, and to analyze the effect of transsphenoidal surgery on sleep apnea.


Eligibility criteria: Inclusion Criteria:

* patients with newly diagnosed acromegaly

Exclusion Criteria:

* patients who can not undergo transsphenoidal surgery

Primary outcomes:
measure: Change in Respiratory disturbance index
timeFrame: Baseline and 3 months after transsphenoidal surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT00818116: Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL
Official title: Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric Intraocular Lens (IOL): Postmarket Evaluation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cataracts
Keywords: Cataract
visual acuity
AcrySof ReSTOR Aspheric Intraoculare Lens
Bilateral cataract
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2009-01-07
Enrollment: 34
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate postoperative visual function in patients implanted bilaterally with the ReSTOR Aspheric Intraocular Lens (IOL).


Eligibility criteria: Inclusion Criteria:

* Bilateral cataract patients who require natural crystalline lens removal and bilateral Intraocular Lens (IOL) implantation.
* 50\~75 years of age
* \<1 Diopter of astigmatism preoperatively (before surgery) as measured by Keratometry readings.

Exclusion Criteria:

* Patients with pre-existing conditions that could skew the results.
* Any of conditions before and during surgery specified in the product information.

Primary outcomes:
measure: Uncorrected and Best Corrected Visual Acuities (Near and Distance)
timeFrame: 6 Months Following Cataract Surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Alcon Call Center for Trial Locations
state: Texas
Study officials:
References:
Clinical trial NCT00664716: Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants
Official title: Assessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis
RA
DMARD inadequate response
Methotrexate
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2008-04-23
Enrollment: 391
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Safety and efficacy of BG9924 in RA participants that have had an inadequate response to disease-modifying anti-rheumatic drug (DMARD) therapy.


Eligibility criteria: Key Inclusion Criteria:

* Diagnosis of RA (functional class I - III)
* Stable dose of MTX
* Inadequate response to at least one conventional DMARD therapy

Key Exclusion Criteria:

* Serious local infection or systemic infection
* History (Hx) of recurrent infections requiring oral or parenteral anti-infective treatment
* Hx of tuberculosis (TB) or positive purified protein derivative (PPD) test during the screening period
* Clinical significant lab tests at screening
* Positive for Hep C or Hep B at screening

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcomes:
measure: Evaluate efficacy of BG9924 in combination with methotrexate (MTX) in RA participants who have had an inadequate response to DMARD therapy
timeFrame: 3 months
Secondary outcomes:
measure: Assess the safety and tolerability of BG9924 in this participant population
timeFrame: 3 months
Other outcomes:
Locations:
city: Tucuman
country: Argentina
facility: Coordinating Research Site
city: Sao Paulo
country: Brazil
facility: Coordinating Research Site
city: Budapest
country: Hungary
facility: Coordinating Research Site
city: Cuernavaca
country: Mexico
facility: Coordinating Research Site
city: Torun
country: Poland
facility: Coordinating Research Site
city: Braila
country: Romania
facility: Coordinating Research Site
city: Moscow
country: Russian Federation
facility: Coordinating Research Site
city: Leeds
country: United Kingdom
facility: Coordinating Research Site
state: Yorkshire
Study officials:
affiliation: Biogen
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Bienkowska J, Allaire N, Thai A, Goyal J, Plavina T, Nirula A, Weaver M, Newman C, Petri M, Beckman E, Browning JL. Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS One. 2014 Nov 18;9(11):e112545. doi: 10.1371/journal.pone.0112545. eCollection 2014.
Clinical trial NCT02294916: Pediatric Intubation by Nurses
Official title: Comparison of Pentax-AWS Airwayscope, Intubrite, AirTraq and Miller Laryngoscope for Tracheal Intubation by Nurses During Chest Compression in a Pediatric Manikin: A Randomised Crossover Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Intubation
Cardiac Arrest
Lead sponsor: International Institute of Rescue Research and Education
Sponsor class: OTHER
First posted: 2014-11-19
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to compare the Pentax AWS, Intubrite and AirTraq to Miller laryngoscope during pediatric resuscitation with and without chest compressions.

Detailed description: Endotracheal intubation (ETI) is a life-saving procedure performed daily in emergency medicine. The European Resuscitation Council (ERC) 2010 cardiopulmonary resuscitation (CPR) guidelines suggest that intubators should be able to secure the airway without interrupting chest compression. However, ETI with uninterrupted chest compression in patients can be a very difficult skill to acquire.

Eligibility criteria: Inclusion Criteria:

* give voluntary consent to participate in the study
* minimum 1 year of work experience in emergency medicine
* experienced emergency medical personnel - nurses

Exclusion Criteria:

* not meet the above criteria
* wrist or low back diseases

Primary outcomes:
measure: Time to intubation
timeFrame: 1 day
Secondary outcomes:
measure: Success of intubation
timeFrame: 1 day
measure: VAS score
timeFrame: 1 day
measure: Cormack-Lehan scale
timeFrame: 1day
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: International Institute of Rescue Research and Education
state: Masovia
Study officials:
affiliation: Institute of Cardiology
name: Lukasz Szarpak
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01501916: Effect of Vitamin D3 on Cardiovascular Risk Factors
Official title: Effect of Vitamin D3 on Cardiovascular Risk Factors: a Randomized Trial in Human
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertensive Disease
Deficiency of Vitamin D3
Lead sponsor: Martin-Luther-Universität Halle-Wittenberg
Sponsor class: OTHER
Collaborators: name: German Federal Ministry of Education and Research
First posted: 2011-12-30
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate whether a supplementation of Vitamin D3 can be used to reduce atherosclerotic risk factors.

Detailed description: It is the objective of this study to investigate whether a supplementation with Vitamin D3 can be used to reduce atherosclerotic risk factors such as hypertension, inflammation and hyperlipidemia. The research question is whether Vitamin D3 can lower blood pressure in mildly hypertensive subjects who are naive to antihypertensive medication, whether Vitamin D reduces the level of systemic inflammation and whether Vitamin D3 has an effect on blood lipids.

major outcomes:

- decrease of systolic blood pressure in the treatment group in comparison with the placebo group

Eligibility criteria: Inclusion Criteria:

* human volunteers with mild hypertension

Exclusion Criteria:

* use of antihypertensive medication
* use of vitamin d or calcium supplements
* known renal, inflammatory or malignant diseases
* hypercalcemia or hypercalciuria
* participation in other clinical studies
* use of tanning booths during the study

Primary outcomes:
measure: blood pressure
timeFrame: after 8 weeks of supplementation
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Institut für Agrar- und Ernährungswissenschaften
name: Jutta Dierkes, Prof. Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06371716: Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions
Official title: Application of a New System of Ultrasound (US) Guided - Radiofrequency Ablation (RFA) on Explanted Pancreas From Patients With Solid Pancreatic Masses: Study of Efficacy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Pancreatic Cancer
Endoscopic Ultrasound
Radiofrequency Ablation
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2024-04-17
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 15 resected PDAC without neoadjuvant treatment 15 resected PDAC with neoadjuvant treatment 15 resected neuroendocrine tumors

Each group (15 patients each) Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)
Primary purpose: TREATMENT

Brief summary: The study investigates the feasibility and the efficacy to treat pancreatic solid lesions as pancreatic adenocarcinomas (PDAC) and neuroendocrine tumors (NET) with ex-vivo radiofrequency ablation (RFA) under ultrasound (US) control.

The study intent is to define the optimal radiofrequency ablation POWER of the system in terms of maximum sizes (diameters) of histological coagulative necrosis obtained at pathological samples. Results will be useful to define the optimal settings to ablate pancreatic solid lesions (PDAC and neuroendocrine tumours).

Detailed description: A probe specifically designed for Endoscopic Ultrasound (EUS) in vivo treatment of human pancreatic solid masses will be used. The probe is connected to a radiofrequency generator on which the power can be set and the tip of the probe (on the tip is present the radiofrequency electrode) is continuously perfused by chilled solution. The generator can stop the power supply when the tissue impedance goes beyond the threshold value to prevent tissue carbonization

Eligibility criteria: Inclusion Criteria: pancreatic solid lesion presence (pancreatic adenocarcinoma and neuroendocrine tumors) resected during pancreatic surgery -

Exclusion Criteria: no signature on informed consent

-

Primary outcomes:
measure: diameter (millimeters) of coagulative necrosis obtained by RadioFrequency Ablation
timeFrame: within 15-20 days
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: IRCCS San Raffaele Hospital
Study officials:
References:
Clinical trial NCT03397316: Evaluation of Marginal Bone Loss After Immediate Implant Placement in Esthetic Zone Without Xenograft.
Official title: Evaluation of Marginal Bone Loss After Immediate Implant Placement in Maxillary Esthetic Zone With and Without Xenograft.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bone Loss
Keywords: immediate implant
upper esthetic zone
marginal bone loss
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-01-12
Enrollment: 8
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Marginal bone loss in immediate implant placement in upper esthetic zone by comparing between non grafting in immediate implant placement with xenograft placement in other side.

the study is to assess the marginal bone loss in the two techniques and compare results between them.

Detailed description: Marginal bone loss in immediate implant placement in upper esthetic zone by comparing between non grafting in immediate implant placement with xenograft placement in other side.

the study is to assess the marginal bone loss in the two techniques and compare results between them after follow up period of 4 months.

Eligibility criteria: Inclusion Criteria:

* Adult patients with badly broken teeth in upper esthetic zone indicated for extraction presence of at least 4 mm of bone beyond root apex

Exclusion Criteria:

* presence of fenestrations or dehiscences of the residual bony walls after extraction heavy smokers more than 20 cigarettes per day. systemic diseases that may affect normal healing. psychiatric problems.

Primary outcomes:
measure: marginal bone loss
timeFrame: 4 months
Secondary outcomes:
measure: patient satisfaction
timeFrame: 4 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT05059496: Effects of Hamstring Stretching Using Pressure Biofeedback Unit in Patients With Low Back Pain.
Official title: Effects of Hamstring Stretching Using Pressure Biofeedback Unit in Patients With Low Back Pain.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Low Back Pain
Keywords: Hamstring length
Low back Pain
Pressure Biofeedback unit
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2021-09-28
Enrollment: 38
Sex: ALL
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the effects of Hamstring stretching using a pressure Biofeedback unit on muscle length, pain, and functional status in patients with low back pain.

Detailed description: Several studies have been conducted regarding hamstring stretching with the pelvis anteriorly tilted for treating low back pain but there is very little evidence regarding the use of a pressure biofeedback unit for maintaining anterior pelvic tilt so this study aims to find out whether the hamstring stretching while maintaining anterior pelvic tilt using pressure biofeedback is more effective than hamstring stretching without using pressure biofeedback in patients with low back pain.

Eligibility criteria: Inclusion Criteria:

* Patients with non-specific low back pain
* Chronic pain \> 3 months
* Participants having (ODI) score minimum 20% to 40%
* Participants with hamstrings shorter than 70 degrees bilaterally
* Participants who scored 3 or more than 3 on the Numeric Pain Rating Scale (NPRS)

Exclusion Criteria:

* History of fracture and surgery
* Patients with osteoarthritis and spondylolisthesis
* Patients with systemic disease except for diabetes mellitus and hypertension
* Patients with disc herniation and leg length discrepancy
* Pregnant females
* Participants with severe back pain or excessive lumber lordosis

Primary outcomes:
measure: Hamstring Length
timeFrame: 12 days
Secondary outcomes:
measure: Pain through NPRS
timeFrame: 12 days
measure: Functional Status
timeFrame: 12 days
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Railway General Hospital
state: Punjab
Study officials:
affiliation: Riphah International University
name: Momena Shahzad, MS-OMPT
role: PRINCIPAL_INVESTIGATOR
References: